Clinical guidelines have recommended that KRAS mutational status be determined in all patients with metastatic colorectal cancer that are being considered for anti‐EGFR therapies.
• ~40% of colorectal samples were positive for KRAS mutations
• The most common mutation observed in KRAS was p.G12D
• 4.6% of all mutations observed in KRAS